Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (9557)	6/23/2006 2:02:07 AM
From: John Metcalf	Respond to of 10280

"The non-compete requirement was mentioned explicitly on the CC." I didn't read the entire license agreement, but did search for terms like "termination" and "competition", without finding language that says Pfizer will not compete in the general area of hypnotic or somniferic. Can you suggest another search? Maybe something like "best effort" or "exclusive"? Or you could look at the 10-K on EDGAR and tell us what you find. The license agreement for Indiplon is attached to the 10-K for 2002.

To: DewDiligence_on_SI who wrote (9557)	6/23/2006 2:02:31 AM
From: John Metcalf	Read Replies (1) \| Respond to of 10280

"The non-compete requirement was mentioned explicitly on the CC." I didn't read the entire license agreement, but did search for terms like "termination" and "competition", without finding language that says Pfizer will not compete in the general area of hypnotic or somniferic. Can you suggest another search? Maybe something like "best effort" or "exclusive"? Or you could look at the 10-K on EDGAR and tell us what you find. The license agreement for Indiplon is attached to the 10-K for 2002.